Nephrotoxicity. N17
Conditions
Interventions
Intervention 1: Intervention group: Patients with malignancy who will receive cisplatin with the dose 50-100 mg/m2 will be identified and after signing the consent will be considered for intervention.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Creatinine Clearance higher than 45 mL/min based on Modification of Diet in Renal Disease (MDRD) criterion The patient who will have enough compliance and ability to take melatonin orally. All adult cancer 's patients who will receive a regimen contains cisplatin (with the usual recommended dose between 50-100 mg / m2 )
Exclusion criteria
Exclusion criteria: Patients with active infection or symptoms of sepsis. Patients who have received nephrotoxic drugs such as aminoglycoside, amphotericin, vancomycin, colistin, media contrast, calcineurin inhibitors or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the past 72 hours. Patients who are taking ifosfamide in their chemotherapy regimen Patients who are taking fluvoxamine, anagrelide, or hydroxy progesterone in their treatment regimen. Patients who may experience complications or allergic reactions to melatonin during treatment. Patients who had a history of acute kidney injury ( AKI ) before entering the study. Patients with bilirubin above 2 mg / dl or liver enzymes above 2.5 times the normal level.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of melatonin on cisplatin-induced renal injury according to cheng in Glomerular Filtration Rate (GFR). Timepoint: Measurement of BUN, creatinine, in urine and serum at the time of the previous day, a day and five days after treatment with Cisplatin. Method of measurement: Measurement of urine and serum values by electrolyte analyzer and fordata analysis using Statistical Package for Social Sciences (SPSS).;The effect of melatonin on cisplatin-induced renal injury according to cheng in exertion rate of Na, K and Mg. Timepoint: Measurement of sodium, potassium and magnesium in urine and serum at the time of the previous day, a day and five days after treatment with Cisplatin. Method of measurement: Measurement of urine and serum values by electrolyte analyzer and fordata analysis using Statistical Package for Social Sciences (SPSS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactazade moghaddas
Esfahan University of Medical Sciences
Outcome results
None listed